View Post

Data Presented at ESMO Provides Rationale for Clinical Trial of Onvansertib in Subset of Patients with Highly-Aggressive Triple Negative Breast Cancer

In Clinical Trials by Barbara Jacoby

From: – Significant tumor regression observed with onvansertib in combination with standard-of-care paclitaxel in models of p53-mutated TNBC – Onvansertib preclinical data provides rationale for clinical trial targeting the 80% of TNBC that harbors the p53 mutation – Combination has potential to address critical medical need to provide targeted treatment option to overcome resistance to paclitaxel as single agent …